stoxline Quote Chart Rank Option Currency Glossary
NeuroBo Pharmaceuticals, Inc. (NRBO)
0.4301  0.008 (1.82%)    11-28 15:14
Open: 0.45
High: 0.45
Volume: 9,006
Pre. Close: 0.4224
Low: 0.423
Market Cap: 17(M)
Technical analysis
2023-11-28 3:20:39 PM
Short term     
Mid term     
Targets 6-month :  0.51 1-year :  0.53
Resists First :  0.43 Second :  0.46
Pivot price 0.43
Supports First :  0.4 Second :  0.33
MAs MA(5) :  0.42 MA(20) :  0.43
MA(100) :  0.48 MA(250) :  0.64
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  36.2 D(3) :  39.3
RSI RSI(14): 45.8
52-week High :  2.32 Low :  0.36
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NRBO ] has closed above bottom band by 29.2%. Bollinger Bands are 75.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.45 - 0.45 0.45 - 0.46
Low: 0.41 - 0.42 0.42 - 0.42
Close: 0.42 - 0.42 0.42 - 0.43
Company Description

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Headline News

Mon, 13 Nov 2023
NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial ... - PR Newswire

Mon, 06 Nov 2023
NeuroBo Pharmaceuticals Strengthens Board of Directors with the ... - PR Newswire

Tue, 17 Oct 2023
NeuroBo to Present at the H.C. Wainwright 7th Annual NASH ... - PR Newswire

Fri, 29 Sep 2023
The Zacks Analyst Blog Highlights Molina Healthcare, Dr. Reddy's Laboratories and NeuroBo Pharmaceuticals - Yahoo Finance

Fri, 15 Sep 2023
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a ... - PR Newswire

Wed, 02 Aug 2023
NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera ... - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 39 (M)
Shares Float 37 (M)
Held by Insiders 50.1 (%)
Held by Institutions 1.1 (%)
Shares Short 90 (K)
Shares Short P.Month 122 (K)
Stock Financials
EPS -5.49
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.56
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -45.8 %
Return on Equity (ttm) -86.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.33
Qtrly Earnings Growth 0 %
Operating Cash Flow -9 (M)
Levered Free Cash Flow -3 (M)
Stock Valuations
PE Ratio -0.08
PEG Ratio 0
Price to Book value 0.76
Price to Sales 0
Price to Cash Flow -1.81
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android